Search Results - "Miller, K.D."

Developing DCE-CT to Quantify Intra-Tumor Heterogeneity in Breast Tumors With Differing Angiogenic Phenotype by Minsong Cao, Yun Liang, Changyu Shen, Miller, K.D., Stantz, K.M.

“…The objective of this study is to evaluate the ability of dynamic contrast enhanced computed tomography (DCE-CT) to assess intratumor physiological…”
Get full text

Use and Outcomes of Mechanical Circulatory Support for Myocarditis in Pediatric and Adult Patients in the United States by Rossano, J.W, Miller, K.D, O’Connor, M.J, Lin, K.Y, Mascio, C.E, Rame, J.E, Gaynor, J.W, Ravishankar, C, Shaddy, R.E

Get full text

The effect of ractopamine hydrochloride (Paylean ®) on lean carcass yields and pork quality characteristics of heavy pigs fed normal and amino acid fortified diets by Carr, S.N., Hamilton, D.N., Miller, K.D., Schroeder, A.L., Fernández-Dueñas, D., Killefer, J., Ellis, M., McKeith, F.K.

“…Effects of ractopamine hydrochloride (RAC) on carcass parameters in heavy weight (133.24 ± 8.07 kg) finishing pigs ( n = 278) given amino acid fortified (AA)…”
Get full text

127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) by Miller, K.D., Emens, L.A., Tolaney, S.M., Hurvitz, S.A., Hamilton, E., Paton, V., Hannah, A.L., Boni, V.

Get full text

382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer by Lin, N.U., Borges, V.F., Patel, M.R., Okera, M., Meisel, J., Wesolowski, R., Pluard, T., Miller, K.D., McCarthy, N.J., Conlin, A.K., Mahtani, R., Sabanathan, D., McCann, K.E., Roesch, E., Mathauda-Sahota, G., Schroeder, J., Hamilton, E.P.

Get full text

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 by Parsons, H.A., Blewett, T., Chu, X., Sridhar, S., Santos, K., Xiong, K., Abramson, V.G., Patel, A., Cheng, J., Brufsky, A., Rhoades, J., Force, J., Liu, R., Traina, T.A., Carey, L.A., Rimawi, M.F., Miller, K.D., Stearns, V., Specht, J., Falkson, C., Burstein, H.J., Wolff, A.C., Winer, E.P., Tayob, N., Krop, I.E., Makrigiorgos, G.M., Golub, T.R., Mayer, E.L., Adalsteinsson, V.A.

“…We aimed to examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients with…”
Get full text

596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours by Powderly, J., Shimizu, T., Lorusso, P., Razak, A., Miller, K.D., Balar, A.V., Bruix, J., Michel, L.S., Blaney, M., Guan, X., Lacy, S., Lally, S., Lambert, S., Leibman, R., Vosganian, G., Golan, T., Tolcher, A.

Get full text

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer by Mayer, E.L., Gnant, M.I., DeMichele, A., Martin, M., Burstein, H., Prat, A., Rubovszky, G., Miller, K.D., Pfeiler, G., Winer, E.P., Zdenkowski, N., Anderson, D., Nowecki, Z., Loibl, S., Fohler, H., Metzger, O., Fumagalli, D., Puyana Theall, K., Fesl, C., Dueck, A.

Get full text

(753) - Real-world Continuous Physiologic Monitoring in Pediatric Cardiomyopathy Patients: A Safety and Feasibility Study by Lebo, C.A., Lin, K.Y., O'Connor, M.J., Griffis, H., McBride, M., Miller, K.D., Ryan, R., Shaddy, R.E., Rossano, J.

Get full text

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC) by Loibl, S., Metzger, O., Mandrekar, S.J., Mundhenke, C., Seiler, S., Valagussa, P., DeMichele, A., Lim, E., Tripathy, D., Winer, E.P., Huang, C., Carey, L., Francis, P., Miller, K.D., Goetz, M.P., Prat, A., Loi, S., Krop, I., Gianni, L., Ciruelos, E.M.

Get full text

Determination of low-level pesticide residues in soft drinks and sports drinks by liquid chromatography with tandem mass spectrometery: collaborative study by Miller, K.D, Milne, P

Get full text

Scenarios, Real Options and Integrated Risk Management by Miller, Kent D., Waller, H.Gregory

“…In the 1970s, scenario planning gained prominence as a strategic management tool. Scenario planning encourages managers to envision plausible future states of…”
Get full text

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival by Miller, K. D., Weathers, T., Haney, L. G., Timmerman, R., Dickler, M., Shen, J., Sledge Jr, G. W.

“…Background: As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in…”
Get full text

Exploiting the hallmarks of cancer: the future conquest of breast cancer by Sledge, G.W, Miller, K.D

“…What separates a malignant from a normal cell? This question has occupied scientists for decades. Although a simple answer remains elusive, several hallmarks…”
Get full text

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group by Miller, K.D., O’Neill, A., Perez, E.A., Seidman, A.D., Sledge, G.W.

“…E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor…”
Get full text

Exploiting the hallmarks of cancer by Sledge, G.W, Miller, K.D

Get full text

A Phase II Clinical Trial of ENMD-2076 in Metastatic Triple-Negative Breast Cancer: Translating a P53-Based Biomarker from Bench to Bedside by Diamond, J.R., Tan, A.C., Pitts, T.M., van Bokhoven, A., Aisner, D., Elias, A.D., Borges, V.F., Miller, K.D., Eckhardt, S.G., Tentler, J.J.

Get full text

Purification, cloning, and heterologous expression of a catalytically efficient flavonol 3-O-galactosyltransferase expressed in the male gametophyte of Petunia hybrida by Miller, K.D, Guyon, V, Evans, J.N.S, Shuttleworth, W.A, Taylor, L.P

“…Flavonols are plant-specific molecules that are required for pollen germination in maize and petunia. They exist in planta as both the aglycone and glycosyl…”
Get full text

Effects of handling intensity and live weight on blood acid-base status in finishing pigs by Hamilton, D.N, Ellis, M, Bertol, T.M, Miller, K.D

“…The objective of this study was to determine the effect of live weight on the plasma acid-base response of pigs subjected to various handling intensities…”
Get full text

Tracking neurons recorded from tetrodes across time by Emondi, A.A, Rebrik, S.P, Kurgansky, A.V, Miller, K.D

“…Tetrodes allow isolation of multiple neurons at a single recording site by clustering spikes. Due to electrode drift and perhaps due to time-varying neuronal…”
Get full text